Polymeric Modification NP Preparation Method % EE* Status References
PLGA emulsion-solvent evaporation 85 in-vitro [14]
PLGA , PLGA-PEG, PCL-PEG nanoprecipitation 70 in-vivo [15]
Poloxamer 188 interfacial deposition >90 in-vitro [16]
TPGS [emulsifier] emulsion-solvent evaporation 100 in-vitro [24]
DLPC [emulsifier] emulsion-solvent evaporation 15-56 in-vitro [28]
DPPC [emulsifier] emulsion-solvent evaporation 34-45 in-vitro [29]
chitosan emulsion-solvent evaporation 75-79 in-vitro [19]
DMAB emulsion-solvent evaporation 47 in-vivo [21]
MMT emulsion-solvent evaporation ~50 in-vitro [30]
MMT
HER2 [targeting]
emulsion-solvent evaporation ~50 in-vitro [31]
RGD [targeting] emulsion-solvent evaporation 60-65 in-vivo [32]
pluronic P85
transferrin [targeting]
nanoprecipitation 70-76 in-vivo [33]
PCL PEO-PCL solvent displacement >95 in-vivo [63, 64]
PCL-pluronic F68 emulsion-solvent evaporation 84 in-vivo [72]
PCL-pluronic F68
DMAB
modified solvent displacement 76-88 in-vivo [193]
mPEG-PCL
Angiopep [targeting]
emulsion and evaporation 90 in-vivo [67, 68]
mPEG-PCL solid dispersion 98 in-vivo [69]
PVP-b-PCL modified nanoprecipitation 85 in-vivo [73]
PEG-PCL co-solvent extraction in-vivo [66]
PEG-PCL
folic acid [targeting]
dialysis in-vitro [70]
PCL-g-PVA dialysis in-vitro [74]
PEtOz-PCL dialysis 5-76 in-vitro [75]
PCL-PEEP
galactosamine [targeting]
dialysis in-vitro [76]
PLA PLA-PEG [diblock] thin film 65 in-vivo [49]
PLA-PEO [star-branch] solvent evaporation 6-56 in-vitro [48]
PVA-PEG solvent evaporation 20-62 in-vitro [50]
Poly[γ-glutamic acid] galactosamine [targeting] solvent evaporation 50-54 in-vivo [51]
PLA-PEG-PLA
PEG-PLA-PEG
solvent evaporation 14-31 in-vivo [52, 53]
Chitosan cholanic acid dialysis 92 in-vivo [78, 194]
oligomer dialysis 97 in-vivo [79]
glyceryl monooleate emulsion-solvent evaporation 98-100 in-vitro [80]
mPEG, cholesterol dialysis 70 in-vivo [81]
N-acetyl histidine in-vitro [82]
stearic acid, glutaraldehyde ultrasonication 94-99 in-vitro [83]
Gelatin desolvation > 80 in-vivo [109-112]
HA desolvation 90 in-vivo [95]
oligomer dialysis in-vitro [96]
PBCA pluronic F127 miniemulsion 80 in-vitro [98]
chitosan dialysis 90 in-vivo [99]
surfactants [dextran 70, cholesterol, PVA, and lecithin] Polymerization 60-80 in-vitro [100]
Albumin high-pressure homogenization approved [88]
CREKA and LyP-1 peptides [targeting] in-vivo [91]
folic acid [targeting] desolvation 95 in-vitro [92]
octaldehyde dialysis 90 in-vitro [93]
HPG PEG, PEI solvent evaporation in-vivo [102]
PEG-PE EPC, solid triglycerides, cationic Lipofectin lipids solvent evaporation ~100% in-vivo [103-106]
Table 1: Summary of PX-loaded Polymeric NPs. [*EE=Entrapment Efficiency].